Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related surgery, and emergency surgery (defined as prostate surgery occurring within 30 days of AUR). The MarketScan database will be utilized for this study (2000-2008).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: 5-alpha Reductase Inhibitors

Criteria

Inclusion Criteria:

• Male

• aged 50 years or older

• diagnostic claim for BPH

• prescription claim for an AB and a 5ARI in the observation period (5ARI must occur within a 6-month window after the AB).

• continuously eligible for 6 months prior to and 12 months after index prescription date

Exclusion Criteria:

• prostate or bladder cancer during the study period

• any prostate-related surgical procedure within 5 months of the index prescription date

• prescription claim for finasteride 1 mg for male pattern baldness during the study period

• 5ARI therapy prior to initiation of AB therapy